US Stock MarketDetailed Quotes

NKTX Nkarta

Watchlist
  • 10.780
  • -0.305-2.75%
Trading Mar 28 14:31 ET
759.19MMarket Cap-4491P/E (TTM)

About Nkarta Company

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Company Profile

SymbolNKTX
Company NameNkarta
Listing Date07/10/2020
Issue Price18.00
Founded2005
CEOMr. Paul J. Hastings
MarketNASDAQ
Employees150
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1150 Veterans Boulevard
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-925-407-1049

Company Executives

  • Name
  • Position
  • Salary
  • Paul J. Hastings
  • Chief Executive Officer and Director
  • 6.78M
  • Dr. Alicia J. Hager, PhD
  • Chief Legal Officer and Corporate Secretary
  • 3.28M
  • Dr. Nadir Mahmood, PhD
  • Principal Accounting Officer, Chief Financial Officer and Business Officer
  • 2.55M
  • Dr. James Trager, PhD
  • Chief Scientific Officer
  • --
  • Dr. Ralph Brandenberger, PhD
  • Chief Technical Officer
  • --
  • Dr. David Shook
  • Chief Medical Officer
  • --
  • Alyssa Levin
  • Chief Financial Officer, Chief Business Officer and Principal Accounting Officer
  • --
  • Dr. Ali Behbahani, M.B.A.,M.D.
  • Chairman of the Board
  • 350.51K
  • Leone D Patterson
  • Independent Director
  • 320.01K
  • Dr. Simeon J. George, M.B.A.,M.D.
  • Independent Director
  • 310.01K
  • Dr. Michael Dybbs, PhD
  • Independent Director
  • 319.01K
  • Angela Thedinga
  • Independent Director
  • --
  • Dr. Fouad Azzam, M.B.A.,PhD
  • Independent Director
  • 312.51K
  • Dr. Zachary Scheiner, PhD
  • Independent Director
  • 309.01K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg